InvestorsHub Logo
Followers 88
Posts 5985
Boards Moderated 0
Alias Born 03/19/2007

Re: Alydyr post# 26590

Wednesday, 08/26/2015 6:04:29 AM

Wednesday, August 26, 2015 6:04:29 AM

Post# of 97081
I would say, that this Kind of press-release Shows who is desperate and who not. Just because of being a Monopolist with unlimited funds does not mean that at the end law will not dictate them the costly outcome in favour of DECN. WELL WELL - J&J is running out of Options if the term" J&J RECENTLY FILED THEIR FINAL APPEAL. Not much left for them afterwards if the word FINAL has any meaning. The legal and financial backers of DECN will get their day, this is for sure.



Having received successive unfavorable legal patent decisions concerning its '105 patent, Johnson & Johnson recently filed their final appeal in an attempt to maintain exclusivity over the blood glucose test market. Prior appellate court rulings have consistently affirmed that Pharma Tech's GenStrip legally and justifiably entered the market to compete with the Lifescan franchise. Those rulings have been specific in their opinion and narrowly precise in the interpretation of the law. The clarity and comprehensiveness of the recent USPTO decision effectively neutralized a cogent legal basis for appeal. Desperate to extend the legal process, the most recent J&J/Lifescan appeal necessarily attacked not just the law and the ruling against them, but also the Director of the USPTO and challenged the rights to render a decision as per agency dictates.


http://www.marketwatch.com/story/us-solicitor-general-intervenes-against-johnson-johnson-in-decns-long-running-patent-battle-over-genstrip-50-2015-04-14